On Monday shares of Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) closed at $6.80. Company’s sales growth for last 5 years was 3.60% and EPS growth for next 5 years is recorded as 1.50%. Brazil’s government nominated Murilo Ferreira, chief executive officer of miner Vale, to head the board of directors of Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), the embattled state-run oil company said. Ferreira will replace former Brazilian finance minister Guido Mantega, who resigned. Luciano Coutinho, president of state development bank BNDES, was named interim chairman.
BIND Therapeutics, Inc. (NASDAQ:BIND) in last trading activity increased 2.72% to close at $5.67. Company weekly performance is 3.28% while its quarterly performance stands at -0.87%. BIND Therapeutics, Inc. (NASDAQ:BIND) is -58.67% away from its 52 week high. BIND Therapeutics, Inc. (NASDAQ:BIND) announced that it has extended the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline.
Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) in last trading activity moved down -0.63% to close at $23.54. Company weekly performance is 2.62% while its quarterly performance stands at 5.66%. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) is -7.03% away from its 52 week high. EDA vendor Cadence Design Systems Inc. says its digital and custom/analog design tools have achieved certification for Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM))’s current 10nm FinFET design rule manual and Spice models. Cadence (San Jose, Calif.) says its custom/analog and digital implementation and signoff tools have been certified by TSMC on high-performance reference designs in order to provide customers with the fastest path to design closure on the 10nm FinFET process.
Actavis plc (NYSE:ACT) has 0.20% insider ownership while its institutional ownership stands at 62.70%. In last trading activity company’s stock closed at $297.84. Actavis plc (NYSE:ACT) confirmed that it is seeking FDA approval for its generic version of Gilead Sciences, Inc.’s Letairis (5 mg and 10 mg). Letairis is approved for the treatment of pulmonary arterial hypertension. Gilead and Royalty Pharma Collection Trust have filed a patent infringement lawsuit against Actavis in the U.S. District Court for the District of Delaware in order to prevent Actavis from commercializing its generic version of Letairis prior to the expiration of U.S. Patent No. RE42,462.
On last trading day Coach, Inc. (NYSE:COH) increased 1.48% to close at $42.48. Its volatility for the week is 1.55% while volatility for the month is 1.69%. COH’s sales growth for past 5 years was 8.30% and its EPS growth for past 5 years was 7.90%. Coach, Inc. (NYSE:COH) monthly performance is 0.88%. KeyBanc upgraded shares of Coach (NYSE:COH) to an overweight rating in a research report released on Monday morning. KeyBanc currently has $50.00 price objective on the stock.